Document Detail

The Role of Natriuretic Peptides as Biomarkers for Guiding the Management of Chronic Heart Failure.
MedLine Citation:
PMID:  23187878     Owner:  NLM     Status:  Publisher    
The current standard treatment of chronic heart failure (HF) is based on clinical judgment, with the goal of achieving the maximally tolerated therapeutic program. The complexity of this approach may contribute to the well-established treatment gaps that exist in HF management; consequently, the risks for morbidity and mortality in this population remain extremely high. Alternative means are needed to improve the outcomes of patients with HF. Natriuretic peptides are biological markers for HF disease-its presence, severity, and prognosis-and show unique interactions with therapeutics known to have benefit in HF. Accordingly, interest has recently developed in "biomarker-guided" care for HF. This approach involves applying these assays to identify patients in need of therapy intensification and to provide an objective "monitor" of disease status. This review examines the biology of natriuretic peptides, discusses the rationale for their use in HF, and details the aggregate experience gained thus far in biomarker-guided care.Clinical Pharmacology & Therapeutics (2012); advance online publication 28 November 2012. doi:10.1038/clpt.2012.187.
S R Motiwala; J L Januzzi
Related Documents :
14992688 - The ftr1p iron permease in the yeast plasma membrane: orientation, topology and structu...
12824038 - Design and application of a peptide nucleic acid sequence targeting the p75 neurotrophi...
18424768 - A protein complex in the brush-border membrane explains a hartnup disorder allele.
18249138 - Homology modeling of breast cancer resistance protein (abcg2).
19785168 - Vibrational spectroscopy of a non-aromatic amino acid-based model peptide: identificati...
23768138 - Reversal of the hofmeister series: specific ion effects on peptides.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-28
Journal Detail:
Title:  Clinical pharmacology and therapeutics     Volume:  -     ISSN:  1532-6535     ISO Abbreviation:  Clin. Pharmacol. Ther.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372741     Medline TA:  Clin Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Effect of structural defects and chemical functionalisation on the intrinsic mechanical properties o...
Next Document:  Serum levels of ?-glutamyltransferase and progression of coronary atherosclerosis.